Precision Medicine in Oncology®

Single-agent vorasidenib or ivosidenib led to brain penetrance and 2-hydroxyglutarate suppression in patients with low-grade glioma who harbor IDH1 mutations.

Joseph A. Sparano, MD, discusses using gene expression profiles as a means to guide therapy in breast cancer.

Updated guidelines from the United States Preventive Services Task Force on BRCA1/2 genetic testing recommend risk assessment, counseling, and genetic test-ing for women who meet certain criteria but fall short of encompassing important groups of individuals who are at risk for developing BRCA1/2 mutation–driven disease

In the ongoing search for novel immunotherapies that might rival or surpass the efficacy of immune checkpoint inhibitors, drugs targeting IDO1—a key enzyme in tryptophan metabolism—have been a major focus in recent years.

James P. Stevenson, MD, discusses available biomarker-driven therapies in non–small cell lung cancer, as well as rarer biomarkers under clinical investigation.

R. Steven Paulson, MD, discusses how to adapt to the era of precision medicine, the latest with liquid biopsies, and a unique diagnostic tool with the potential to revolutionize oncology.

Sreeni Chittoor, MD, FACP, discusses the role of liquid biopsies in non–small cell lung cancer and the advantages of using this type of assay compared with tissue-based genotyping across cancer types. 

Evidence is increasing that blood-based biomarkers have predictive utility in advanced non–small cell lung cancer. Going further, blood-based next-generation sequencing appears to have clinical utility in selecting targeted treatment in this setting.

Faculty from Texas Oncology and Quest Med Fusion highlight exciting ongoing research efforts at their respective institutions.